Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3251
Arts-Way Manufacturing Co
ARTW
$18.5M
| $117K | ﹤0.01% |
49,674
+25,174
| +103% | +$53.1K |
2017 Q1
13 quarters
|
|
3252
Jerash Holdings
JRSH
$77.5M
| $117K | ﹤0.01% |
24,084
+2,600
| +12% | +$12.3K |
2019 Q3
3 quarters
|
|
3253
GigaMedia
GIGM
$15.3M
| $115K | ﹤0.01% |
+36,350
| New | +$94.7K |
2020 Q2
0 quarters
|
|
3254
Ranger Energy Services
RNGR
$362M
| $115K | ﹤0.01% |
38,987
+6,700
| +21% | +$24.1K |
2019 Q2
4 quarters
|
|
3255
VolitionRx Ltd
VNRX
$6.48M
| $112K | ﹤0.01% |
+1,439
| New | +$104K |
2020 Q2
0 quarters
|
|
3256
Arbutus Biopharma
ABUS
$844M
| $111K | ﹤0.01% |
+61,207
| New | +$100K |
2020 Q2
0 quarters
|
|
|
CD
3257
Chaince Digital Holdings
CD
$966M
| $111K | ﹤0.01% |
43,462
+6,746
| +18% | +$12.3K |
2017 Q4
10 quarters
|
|
|
MRNS
3258
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $111K | ﹤0.01% |
+10,950
| New | +$101K |
2020 Q2
0 quarters
|
|
|
ESBK
3259
DELISTED
Elmira Savings Bank Elmira NY
ESBK
| $111K | ﹤0.01% |
10,068
-3,574
| -26% | -$42.1K |
2017 Q3
11 quarters
|
|
3260
Capital Bancorp
CBNK
$631M
| $110K | ﹤0.01% |
10,274
-17,600
| -63% | -$190K |
2019 Q3
3 quarters
|
|
|
CWBR
3261
DELISTED
CohBar, Inc. Common Stock
CWBR
| $110K | ﹤0.01% |
+2,365
| New | +$165K |
2020 Q2
0 quarters
|
|
|
CYAD
3262
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| $110K | ﹤0.01% |
+10,300
| New | +$101K |
2020 Q2
0 quarters
|
|
3263
DarioHealth
DRIO
$56.8M
| $109K | ﹤0.01% |
+855
| New | +$114K |
2020 Q2
0 quarters
|
|
3264
Ramaco Resources Class A
METC
$552M
| $108K | ﹤0.01% |
52,268
+31,215
| +148% | +$73.9K |
2019 Q4
2 quarters
|
|
3265
Myomo
MYO
$57.4M
| $107K | ﹤0.01% |
29,022
+12,100
| +72% | +$47.2K |
2019 Q1
5 quarters
|
|
3266
Rockwell Medical
RMTI
$32.2M
| $107K | ﹤0.01% |
497
-159
| -24% | -$37.6K |
2019 Q4
2 quarters
|
|
|
SOS
3267
SOS Limited
SOS
$5.72M
| $106K | ﹤0.01% |
51
+4
| +9% | +$4.64K |
2019 Q2
4 quarters
|
|
|
DRK
3268
DarkHorse Technologies Inc. Common Shares
DRK
$29.7M
| $105K | ﹤0.01% |
+525
| New | +$63K |
2020 Q2
0 quarters
|
|
|
KUST
3269
Kustom Entertainment Inc
KUST
$2.58M
| – | – |
0
| – | – |
2020 Q2
0 quarters
|
|
3270
Vuzix
VUZI
$214M
| $105K | ﹤0.01% |
+44,100
| New | +$91.2K |
2020 Q2
0 quarters
|
|
|
NVNO
3271
enVVeno Medical
NVNO
$6.08M
| $104K | ﹤0.01% |
+309
| New | +$102K |
2020 Q2
0 quarters
|
|
|
NHLD
3272
DELISTED
National Holdings Corporation
NHLD
| $104K | ﹤0.01% |
52,108
+1,800
| +4% | +$3.27K |
2018 Q2
8 quarters
|
|
3273
Riley Exploration Permian
REPX
$1B
| $101K | ﹤0.01% |
15,216
+1,659
| +12% | +$10.7K |
2017 Q4
10 quarters
|
|
3274
One Stop Systems
OSS
$192M
| $100K | ﹤0.01% |
50,700
-8,210
| -14% | -$13.6K |
2019 Q4
2 quarters
|
|
|
SELF
3275
Global Self Storage
SELF
$56.1M
| $100K | ﹤0.01% |
26,000
+6,500
| +33% | +$24.8K |
2016 Q3
15 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.